TY - JOUR
T1 - Effects of guar gum supplementation on the lipid profile
T2 - A systematic review and meta-analysis of randomized controlled trials
AU - Lin, Jianbei
AU - Sun, Yan
AU - Santos, Heitor O.
AU - Găman, Mihnea Alexandru
AU - Bhat, Latha T.
AU - Cui, Yan
N1 - Publisher Copyright:
© 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University
PY - 2021/11/29
Y1 - 2021/11/29
N2 - Background and aims: Guar gum can be used as an adjuvant in the treatment of dyslipidemia. However, based on data from different studies, the effectiveness of this product is not uniform. Therefore, we conducted a dose–response meta-analysis between guar gum supplementation and lipid profile. Methods and results: Five databases (Scopus, Web of Science, PubMed/Medline, Embase, and Google Scholar) were searched to identify relevant articles published up to July 2020. The weighted mean difference (WMD) was derived based on the random-effects model. Overall findings were generated from 25 eligible trials. Patients’ conditions included hyperlipidemia, diabetes, metabolic syndrome, hypertension, overweight, carotid endarterectomy, and menopausal women. Prescribed gum dose varied between 100 mg/d and 30 g/d for 1–24 months. Compared with control groups, guar gum supplementation decreased total cholesterol (TC) by −20.41 mg/dL (95% CI: −26.76 to −14.07; P < 0.001) and low-density lipoprotein-cholesterol (LDL-C) by −17.37 mg/dL (95% CI: −23.60 to −11.13; P < 0.001), but did not change triglycerides (TG) (WMD: −6.53 mg/dL, 95% CI: −16.03 to 2.97; P = 0.178) and high-density lipoprotein-cholesterol (HDL-C) (WMD: −0.62 mg/dL, 95% CI: −1.68 to 0.44, P = 0.252). Conclusions: Guar gum supplementation significantly reduced serum LDL-C and TC levels in patients with cardiometabolic problems, but had neutral effects on TG and HDL-C levels.
AB - Background and aims: Guar gum can be used as an adjuvant in the treatment of dyslipidemia. However, based on data from different studies, the effectiveness of this product is not uniform. Therefore, we conducted a dose–response meta-analysis between guar gum supplementation and lipid profile. Methods and results: Five databases (Scopus, Web of Science, PubMed/Medline, Embase, and Google Scholar) were searched to identify relevant articles published up to July 2020. The weighted mean difference (WMD) was derived based on the random-effects model. Overall findings were generated from 25 eligible trials. Patients’ conditions included hyperlipidemia, diabetes, metabolic syndrome, hypertension, overweight, carotid endarterectomy, and menopausal women. Prescribed gum dose varied between 100 mg/d and 30 g/d for 1–24 months. Compared with control groups, guar gum supplementation decreased total cholesterol (TC) by −20.41 mg/dL (95% CI: −26.76 to −14.07; P < 0.001) and low-density lipoprotein-cholesterol (LDL-C) by −17.37 mg/dL (95% CI: −23.60 to −11.13; P < 0.001), but did not change triglycerides (TG) (WMD: −6.53 mg/dL, 95% CI: −16.03 to 2.97; P = 0.178) and high-density lipoprotein-cholesterol (HDL-C) (WMD: −0.62 mg/dL, 95% CI: −1.68 to 0.44, P = 0.252). Conclusions: Guar gum supplementation significantly reduced serum LDL-C and TC levels in patients with cardiometabolic problems, but had neutral effects on TG and HDL-C levels.
UR - http://www.scopus.com/inward/record.url?scp=85115649602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115649602&partnerID=8YFLogxK
U2 - 10.1016/j.numecd.2021.08.040
DO - 10.1016/j.numecd.2021.08.040
M3 - Article
C2 - 34607737
AN - SCOPUS:85115649602
SN - 0939-4753
VL - 31
SP - 3271
EP - 3281
JO - Nutrition, Metabolism and Cardiovascular Diseases
JF - Nutrition, Metabolism and Cardiovascular Diseases
IS - 12
ER -
